Valo Health Completes Enrollment of OPL-0401 Phase 2 Study
Valo Health Announces Changes to its Board of Directors and Leadership Team
WILMINGTON, Mass. & BOSTON--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched LogicaTM, an artificial intelligence (AI) powered drug solution that directly translates clients’ biological insights into optimized preclinical assets. Logica leverages Valo’s AI-powered Opal Computational Platform and Charles River’s leading preclinical expertise, providing clients with transformed drug discovery with a single integrated offering seamlessly translating targets to candidate nomination.
WILMINGTON, Mass. & BOSTON--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, LLC (“Valo”), the technology company using human-centric data and computation powered by artificial intelligence (AI) to transform the drug discovery and development process, today announced the formation of a multiyear strategic partnership. This agreement will combine Valo’s Opal Computational Platform with Charles River’s drug discovery and development capabilities to offer a new transformative, AI-enabled drug discovery and development platform.
In a statement, Khosla said that the decision not to go forward was mutual. No exact reason was given except that it was based on current market conditions in the biotechnology industry. Under the terms of their merger agreement, the deal can be terminated at any time and with neither party having liability provided that mutual written consent is presented.
Flagship’s AI-focused Valo Health will reverse merge with the first of Vinod Khosla’s three blank check companies, the duo announced Wednesday morning, giving Valo access to the $333 million held in the SPAC as well as a $168.5 million PIPE financing. The merger will create a company valued at roughly $2.8 billion, Valo said, and is expected to close before September.
Valo Therapeutics (Valo TX) has partnered with ImmunoScape to identify immunogenic peptides for pan-coronavirus vaccine development.